OB/GYNs, urologists, primary care physicians, endocrinologists, nurses with focus in reproductive/sexual medicine, NPs/PAs, psychiatrists, psychologists/sex therapists, residents/fellows of above disciplines, managed care clinicians, and clinical pharmacists interested in management and treatment of hypoactive sexual desire disorder (HSDD).
Sexual health is an integral component of women’s psychological and overall physical health. Clinicians often perceive the treatment of female sexual health as a quality of life issue and low health priority; furthermore, they often do not believe they possess the knowledge and experience to diagnose and manage HSDD. Even though HSDD significantly impairs their overall sense of well-being, sexual satisfaction, and the quality of their relationships, many patients do not bring up sexual health, due to embarrassment and lack of education on sexual health. Physicians often feel inadequately trained to directly address sexual health and unable to focus on patient concerns due to time-constraints. There is a clear need for education to help clinicians proactively speak to patients about sexual health concerns that patients may consider difficult to discuss, and to facilitate collaboration between specialists in various disciplines that manage women’s health.
At the conclusion of this activity participants should be better able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and CogniMed Inc. TOPEC is accredited by the ACCME to provide continuing medical education for physicians and a certificate of participation to NPs/PAs.
TOPEC designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of TOPEC Clinical Content Review Committee who has no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and balanced.
In accordance with ACCME Standards for Commercial Support, TOPEC requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Sean Barrett has nothing to disclose.
Jeffrey Rosenberg has nothing to disclose.
Dr. Derogatis serves on the Scientific Advisory Board and was a Principal Investigator for AMAG, Palatin, Sprout and Endoceutics Pharma.
Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of CogniMed Inc. or TOPEC. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive on the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely on the information contained within this educational activity.
Jointly provided by
This activity is supported by an independent educational grant provided by AMAG Pharmaceuticals Inc. and Valeant Pharmaceuticals North America LLC.
Next to Webcast